
FairJourney Biologics appoints Dr Werner Lanthaler as CEO
Charlie Blackie-Kelly | October 14, 2025 | Appointment | | FairJourney Biologics
FairJourney Biologics (FJBio), Portuguese antibody discovery and development company, has appointed Dr Werner Lanthaler as its new chief executive officer.
Dr Werner Lanthaler, newly appointed CEO of FairJourney Biologics, said: “Shared data- and AI-driven innovation platforms will be critical to accelerating drug discovery while reducing development timelines and costs.”
Dr Lanthaler brings extensive experience in the biopharmaceutical sector, with a career spanning several decades and a focus on innovation and strategic growth. He previously served as CEO of Evotec for 15 years, overseeing the company’s global expansion and the advancement of its drug discovery and precision medicine capabilities. Before that, he was CFO at Intercell, where he played a key role in the company’s initial public offering and the market launch of its vaccine programme.
Founded in 2012, FJBio provides comprehensive antibody design and development services, including screening, characterisation, engineering, production, biophysical and biochemical analysis, and cell line development.
FJBio’s founder and former CEO, António Parada, will transition to the company’s Supervisory Board, where he will focus on advancing its innovation strategy.
António Parada, supervisory board member of FJBio, said: “FairJourney Biologics is just at the beginning of its mission to lead the field of rapid antibody development. Innovation will hold a central role in helping to drive transformational benefits to our partners.”






